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Abstract
Antimicrobial peptides (AMPs) and synthetic analogues thereof target conserved structures of bacterial cell envelopes and
hence, development of resistance has been considered an unlikely event. However, recently bacterial resistance to AMPs
has been observed, and the aim of the present study was to determine whether bacterial resistance may also evolve against
synthetic AMP analogues, e.g. a-peptide/b-peptoid peptidomimetics. E. coli ATCC 25922 was exposed to increasing
concentrations of a peptidomimetic (10 lineages), polymyxin B (10 lineages), or MilliQ water (4 lineages) in a re-inoculation
culturing setup covering approx. 500 generations. All 10 lineages exposed to the peptidomimetic adapted to 326MIC while
this occurred for 8 out of 10 of the polymyxin B-exposed lineages. All lineages exposed to 326MIC of either the
peptidomimetic or polymyxin B had a significantly increased MIC (16–326) to the selection agent. Five transfers (,35
generations) in unsupplemented media did not abolish resistance indicating that resistance was heritable. Single isolates
from peptidomimetic-exposed lineage populations displayed MICs against the peptidomimetic from wild-type MIC to
326MIC revealing heterogeneous populations. Resistant isolates showed no cross-resistance against a panel of membrane-
active AMPs. These isolates were highly susceptible to blood plasma antibacterial activity and were killed when plasma
concentrations exceeded ,30%. Notably, MIC of the peptidomimetic against resistant isolates returned to wild-type level
upon addition of 25% plasma. Whole-genome sequencing of twenty isolates from four resistant lineages revealed
mutations, in murein transglycosylase D (mltD) and outer-membrane proteins, which were conserved within and between
lineages. However, no common resistance-conferring mutation was identified. We hypothesise that alterations in cell
envelope structure result in peptidomimetic resistance, and that this may occur via several distinct mechanisms.
Interestingly, this type of resistance result in a concomitant high susceptibility towards plasma, and therefore the present
study does not infer additional concern for peptidomimetics as future therapeutics.
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Introduction
Resistance of human bacterial pathogens to conventional
antibiotics has increased drastically worldwide within the last
decades [1]. This has led to an intensified search for safer
alternatives for which resistance is less likely to evolve [2,3]. These
include novel natural compounds with antimicrobial activity [4],
inhibitors of quorum sensing [5,6], and antimicrobial peptides
(AMPs) [7,8]. The latter group comprises host defence molecules
constituting a part of the innate immune defence in all higher
organisms, where they display both direct antimicrobial activity
and a broad range of immuno-modulating effects [9–11].
Development of resistance to AMPs is considered unlikely due to
their co-evolution with bacteria, and moreover their preferred
target is the ‘‘Achilles heel’’ of bacterial cells i.e. their distinct
envelope structure [12]. Consequently, there has been increased
focus on the characterisation of natural AMPs [13,14] and on
semi-synthetic [15–17] and synthetic analogues [18–20], as well as
on the development of these leads into future antibiotics against
human bacterial pathogens.
Exposure of bacteria to antimicrobials typically results in
development of resistance, which is either mutational or adaptive.
The former is considered stable and arises after mutations or
acquisition of a genetic element while the latter term describes an
auto-regulated phenomenon characterised by rapid induction of
resistance in the presence of the drug followed by a reversal to the
sensitive phenotype when drug is absent [21]. The outer
membrane of Gram-negative bacteria, which acts as a semi-
permeable barrier mediating decreased sensitivity to antimicrobial
compounds [22], is a well-known example of the functions of
adaptive resistance. Hence, AMP-induced stress has several times
been shown to activate innate two-component systems leading to
modifications of the cell envelope thereby decreasing the negative
charge or permeability of this barrier [23–27]. However, the
observed decrease in susceptibility is most often lost again once the
exposure to AMP is ended, and it is therefore considered an
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induced tolerance rather than resistance introduced via genetic
alterations.
Since AMPs and their analogues mimic components of the
innate immune defence in humans, development of resistance
towards such compounds could potentially compromise our innate
immune defence [28]. Therefore it is important to consider the
risk and potential consequences of emergence of AMP-resistant
strains before such compounds are to be used for systemic
infections [28,29]. Only very few studies have dealt with this
problem, and in most published work, the possible AMP-induced
mutation frequencies have been compared to the much higher
mutation frequencies usually observed for conventional antibiotics.
In general, previous studies have involved short-time evolution
experiments [30,31]. A single comprehensive study, focusing on
continuous selection towards a magainin 2 analogue (pexiganan),
showed that prolonged exposure to an AMP indeed may result in
heritable resistance [29] despite the consensus that resistance
against AMPs is unlikely to evolve. This clearly indicates that the
resistance issue calls for an increased focus in AMP development
programs.
We have previously described a synthetic approach towards
peptidomimetics exhibiting antimicrobial properties, and in the
present study we investigate a-peptide/b-peptoid peptidomimetics
(Figure 1) possessing a design with alternating N-alkylated b-
alanine (b-peptoid) and a-amino acid units [32,33]. It was
demonstrated that these compounds are active against a range
of nosocomial and food-borne pathogenic bacteria, and we have
also shown that the chain length has a marked influence on
membrane activity [34,35]. Here, we investigate the risk of
resistance development in a human pathogenic bacterium as this is
a key parameter in the assessment of the therapeutic potential of
AMPs and their analogues.
Results
The aim of this study was to determine whether bacterial
resistance could develop following exposure to a synthetic AMP
analogue belonging to the class of antibacterial a-peptide/b-
peptoid peptidomimetics. Additionally, we examined whether such
resistance would hamper elimination of the bacteria by the innate
immune system (exemplified by blood plasma). Also, we sought to
elucidate the underlying molecular mechanisms of the peptidomi-
metic resistance that rapidly and consistently developed during
prolonged exposure to gradually increasing concentrations of this
antibacterial including polymyxin B as reference compound.
Continuous Selection towards AMP Resistance
Escherichia coli ATCC 25922 was continuously re-cultured from a
concentration of 1/16 of the wild-type (wt) MIC until adaptation
to 32 times the wt MIC of either peptidomimetic 1 (i.e. 256 mg/
mL) or polymyxin B (i.e. 32 mg/mL) was reached. This resistance
evolved during 77 inoculations equivalent to approx. 500
generations (i.e. the culture was at each sub-culture diluted
1:100 to a density of ,16107 CFU/mL allowing for 6–7
generations during each of the 77 inoculations). All ten lineages
selected with the peptidomimetic eventually grew at 326wt MIC;
for lineages selected with polymyxin B this was the case for eight
out of ten (Figure 2). It is evident that growth was affected at an
earlier stage for the polymyxin B-exposed lineages, i.e. growth was
inhibited for all strains already after two doublings of the
polymyxin B concentration while two lineages failed to grow
further. For the peptidomimetic-exposed lineages growth was not
visibly inhibited until after four doublings of the concentration of
the peptidomimetic (Figure 2). Only once was the concentration
decreased for a lineage supplemented with peptidomimetic (i.e.
lineage 8) due to lack of growth at 326 wt MIC. After two
additional passages at 166wt MIC the lineage successfully grew at
326wt MIC.
The four controls were transferred into fresh unsupplemented
media simultaneously with the transfer of the two other groups of
lineages. At the time point corresponding to 46wt MIC of the
exposed lineages (i.e. 32 mg/mL for peptidomimetic 1 and 4 mg/
mL for polymyxin B) we investigated the ability of these controls to
grow in the presence of the same concentration as the exposed
lineages. Two controls exposed to peptidomimetic 1 at 46wt MIC
failed to grow but one of the two controls exposed to 46wt MIC of
polymyxin B became outgrown. Growth was retained for three
additional passages at the same concentration of polymyxin B
indicating that the spontaneous mutation rate in the presence of
polymyxin B may be higher than that seen for peptidomimetic 1.
Population MIC after Selection
MIC was determined for the selection agent against revived
outgrown cultures at 326wt MIC of all lineages in the two groups
(Table 1 and 2). Only five out of ten of the freezing stocks of the
peptidomimetic-exposed lineages could be re-cultured in peptido-
mimetic-supplemented media, though all of the eight polymyxin
B-exposed freezing stocks grew well. We ascribe this to stress
induced by freezing for some lineages as the cultures subsequently
grew in unsupplemented substrate with retained resistance. A
dramatic increase in MIC was seen for both the peptidomimetic-
and the polymyxin B-exposed lineages showing that resistance had
developed against the selection agent (Table 1 and 2). For the five
peptidomimetic-exposed lineages, MIC against peptidomimetic 1
was increased to 128–512 mg/mL from an initial level of 8 mg/mL
for the wild-type strain corresponding to a 16- to 64-fold increase.
The eight polymyxin B-exposed lineages all had a MIC value of
32 mg/mL polymyxin B, i.e. a 32-fold increase in MIC as
compared to the wild-type strain. The four controls only showed
minor increases in MIC as compared to the wild-type strain.
We determined potential cross-resistance to the other selection
agent (i.e. peptidomimetic 1 vs. polymyxin B) and to an
aminoglycoside antibiotic (gentamicin) and a cell wall-active
antibiotic (ampicillin). No cross-resistance was found to these two
conventional antibiotics for any of the lineages (not shown). Some
cross-resistance was found against polymyxin B for some of the
peptidomimetic-exposed lineages (2- to 16-fold increase in MIC as
compared to that of the wild type, not shown), and against
peptidomimetic 1 for the polymyxin B-exposed lineages (2- to 8-
Figure 1. Structure of the peptidomimetics used in this study.
The structure of peptidomimetic 1 used for continuous culturing of
Escherichia coli and the structure of peptidomimetics 2 and 3 to which
cross-resistance was demonstrated.
doi:10.1371/journal.pone.0073620.g001
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fold increase in MIC as compared to that of the wild type, not
shown).
Stability of Resistance
To establish whether the acquired resistance was heritable all
lineages were revived in unsupplemented media and then cultured
for five passages (corresponding to ,35 generations) in the
absence of the compound applied for selection. All ten lineages
tolerant to the peptidomimetic were successfully revived, and
again we performed MIC determinations against both selection
agents for all lineages. The lineages exposed to peptidomimetic 1
displayed high levels of resistance against this compound even after
growth in unsupplemented media confirming the heritability of
resistance (Table 1). The ten lineages displayed MIC values
against peptidomimetic 1 between 32 mg/mL (46wt MIC) and
256 mg/mL (326wt MIC); the lowest MIC value was seen for
lineage no. 10 which showed a strong decrease as compared to the
initial level of 256–512 mg/mL indicating that this lineage may be
less stable than the others. Similarly, the MIC for polymyxin B
against the polymyxin B-exposed lineages remained high upon
culturing for five passages (equal to approx. 35 generations) in
unsupplemented media (Table 2). The low level of cross-resistance
seen in the two groups of lineages against peptidomimetic 1 and
polymyxin B, respectively, was lost after removal of the selection
pressure, and became similar to that of the controls (not shown).
Single-culture Isolate MIC after Selection
From each of the lineages cultured at 326wt MIC, ten
individual isolates were randomly selected from plating the
populations on non-selective plates. We chose to focus specifically
Figure 2. Continuous selection of Escherichia coli. Continuous selection exerted by peptidomimetic 1 (A), or by polymyxin B (B) leads to
tolerance in E. coli. Solid lines represent individual lineages. All lineages exposed to the peptidomimetic were cultured up to 326wt MIC (A); for
lineages selected against polymyxin B this was eight out of ten (the last two were not able to grow after two doublings in concentration i.e. at
0.25 mg/mL). Punctuated lines indicate wt MIC of the selective agents (8 mg/mL and 1 mg/mL, respectively).
doi:10.1371/journal.pone.0073620.g002
Table 1. Minimum Inhibitory Concentration (mg/mL) of the adapted E. coli lineages against peptidomimetic 1 immediately after
peptidomimetic adaptation and after 35 generations with no peptidomimetic.
Lineage number MICa against peptidomimetic 1 after selection
MICa against peptidomimetic 1 after 35 generations
w/o selection
1 b 128–256
2 256 256
3 b 128
4 256 128
5 64–128 128
6 b 64–128
7 128 128
8 b 32–64
9 b 128
10 256 32
Control 1c 32 16–32
Control 2 8 8
aMIC values are based on two technical duplicates.
bNot determined due to lack of growth of revived freezing stocks in supplemented media.
cE. coli ATCC 25922 had a wt MIC of 8 mg/mL.
doi:10.1371/journal.pone.0073620.t001
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on the isolates from four of these lineages; lineage no. 2 and no. 4
which had a population MIC of 256 mg/mL, grew well in
peptidomimetic-supplemented media and grew with different
colony morphologies (normal as well as larger more light colonies)
and lineages no. 5 and no. 7, which had a population MIC of
128 mg/mL, grew more slowly than lineages no. 2 and no. 4 in
supplemented media and appeared as homogenous colonies when
plated. To this end, it seemed likely that different genetic events
had occurred in these populations, and that this might be reflected
in the resistance profiles of the isolates from the four populations.
Hence, we determined the MIC against peptidomimetic 1 for the
forty isolates from these four lineages (Figure 3). All four
populations were heterogeneous displaying large differences in
MIC values of individual isolates. The ten isolates from lineage
no. 2 displayed MIC values within the range 8–128 mg/mL
(Figure 3A). Two of the ten isolates appeared to be particularly
unstable; in three biological replicates isolate 2–3 exhibited MIC
values of 8, 16 and 64 mg/mL, while the MIC values for isolate 2–
8 were 16, 64 and 128 mg/mL for the three biological replicates.
Remarkably, from lineage no. 4, eight out of ten isolates exhibited
a MIC value identical to that of the wild type (i.e. 8 mg/mL) while
the other two isolates displayed a 4-fold lower MIC as compared
to that of the lineage population i.e. 256 mg/mL (Figure 3B). This
trend was similar to that of lineage no. 5, where seven out of ten
isolates had the same MIC value as the wild type (i.e. 8 mg/mL)
while none of the other three isolates displayed the same MIC as
the entire population i.e. 128 mg/mL (Figure 3C). Overall, these
two populations were evidently less resistant (or stable) than
lineage no. 2. In contrast to this, the ten isolates from lineage
no. 7, which likely reflects the diversity within the population,
appeared more similar to those of lineage no. 2 (Figure 3A and D).
Hence, these ten isolates displayed MIC values in the range of 8–
128 mg/mL, with the highest values corresponding to the
population MIC (Figure 3D). Differences in colony morphology
were not reflected in a significantly altered MIC value. Addition-
ally, individual colonies were verified as E. coli by 16 S rRNA
sequencing as well as by a range of standard phenotypic tests (not
shown). Therefore it appears that it is a general trend that the vast
majority of cells have a lower MIC than the population as a whole
and that a large degree of heterogeneity exists within the lineage
populations.
Cross-resistance
Since AMPs are almost ubiquitous in nature, the potential of
cross-resistance of peptidomimetic-resistant bacteria to natural
AMPs constitutes an important issue to clarify. Therefore we
determined MIC values against polymyxin B (bacterial), prot-
amine (salmon), KR-12 (a short analogue of the human
cathelicidin LL-37), IsCTp (scorpion), Pep-1-K (viral) and melitin
(honey bee venom) for all twenty isolates from lineages no. 2 and
5. These two lineages were chosen because significant differences
in the level of resistance of individual isolates had been found
between the two (Figure 3). We did not find increased MIC values
for any of these as compared to the wild type (not shown). Next,
the level of cross-resistance towards peptidomimetic 2 (Figure 1)
was addressed. In this case, elevated MIC values were found for all
isolates originating from lineages no. 2 and 5, thus reflecting a
high level of resistance against this closely related peptidomimetic.
Similarly, isolates with wild-type MIC towards peptidomimetic 1
from the same lineages also had considerably lower MIC values
towards peptidomimetic 2 (Figure 4). Furthermore, MIC deter-
mination for another analogue sharing the same backbone design
(i.e. peptidomimetic 3, Figure 1) against the three most resistant
isolates from lineage no. 2 gave MIC levels that were 8 times
higher than seen for the wild type strain (i.e. 4 mg/mL vs. 32 mg/
mL). The evaluation of cross-resistance against different groups of
antimicrobials including conventional antibiotics, natural AMPs
and peptidomimetics confirmed that the developed resistance
appeared to be specific for this type of peptidomimetics.
Effect of Human Blood Plasma on Growth and
Susceptibility
AMP resistance is a potential health risk due to impairment of
our own immune system, and we therefore determined plasma
activity against two high-level resistant isolates, one isolate with a
low level of resistance and one susceptible isolate (Table 3) and
compared this to the effect on the (ancestral) wild-type bacteria to
see whether susceptibility to plasma was unchanged following
Table 2. Minimum Inhibitory Concentration (mg/mL) of the adapted E. coli lineages against polymyxin immediately after
polymyxin adaptation and after 35 generations with no polymyxin.
Lineage number MICa against polymyxin after selection MICa against polymyxin after 35 generations w/o selection
1 b b
2 32 32
3 32 32
4 32 32
5 32 32
6 32 32
7 b b
8 32 32
9 32 32
10 32 32
Control 1c 8 0.5
Control 2 1 0.5–1
aMIC values are based on two technical duplicates.
bNot determined since lineage was unable to grow at 326wt MIC.
cE. coli ATCC 25922 had a wt MIC of 1 mg/mL.
doi:10.1371/journal.pone.0073620.t002
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acquisition of resistance. Consequently, both the ancestral wild-
type E. coli and these four selected isolates were grown in a range
of 25–50% plasma. While the wild type grew well and formed a
visible pellet at 50% plasma concentration, only the two isolates 4–
4 and 5–6, with wt MIC and a slightly increased MIC respectively,
were able to do the same. The two high-level resistant isolates 2–7
and 7-3 (Figure 3) were not able to grow at plasma concentrations
above 30%. Colony counts of cells recovered from wells with high
plasma concentrations gave none or a very low number of
surviving cells showing that high concentrations of plasma was
bactericidal to the peptidomimetic-resistant isolates. When plasma
was heat-treated, a conventional method for inactivation of the
complement system belonging to the innate immune system
[36,37], the two high-level resistant isolates grew well in 50%
plasma similar to the wild type and the isolates with no or low
resistance. No changes were seen in the MIC of hydrogen
peroxide or lysozyme following acquisition of peptidomimetic
resistance for isolate 2–7. Lastly, MIC determination was
performed against the above four isolates in 25% plasma to see
whether the presence of plasma counteracted the mechanism of
resistance. In 25% plasma the MIC value of peptidomimetic 1
against the wild-type E. coli was only marginally affected, i.e. MIC
was decreased from 8 mg/mL in MHB media to 2 mg/mL
(Table 3). This weak potentiation of plasma was also seen for an
isolate with wt MIC, namely 4–4 for which MIC decreased from
8 m/mL to 1–4 mg/ml in the presence of plasma, and for an isolate
5–6, with low levels of resistance where MIC decreased from 32–
64 mg/mL in MHB media to 4–8 mg/mL upon addition of plasma
(Table 3). In contrast a strong potentiation of plasma was seen for
the two highly resistant isolates 2-7 and 7-3, where MIC against
isolate 2–7 decreased from 64–128 mg/mL to 0.25-2 mg/mL in
the presence of plasma and from 128 mg/mL to 1–2 mg/mL for
isolate 7-3 (Table 3).
Fitness Cost
An important aspect of bacterial resistance towards AMPs and
their analogues is to determine whether acquisition of resistance
affects the growth potential of the bacterium. Thus, the growth
rates of the forty isolates, obtained from lineages no. 2, 4, 5 and 7,
were compared with that of the wild-type strain in the absence of
peptidomimetic. The thirty isolates from lineages no. 2, 4 and 5
grew with the same growth rate as wild-type E. coli ATCC 25922
Figure 3. Heterogeneity in lineage populations. Minimum Inhibitory Concentration (MIC) for peptidomimetic 1 against population isolates of
lineage no. 2 (A), lineage no. 4 (B), lineage no. 5 (C) and lineage no. 7 (D). Bars indicate biological replicates; MIC for all isolates was determined twice,
a third replicate was performed for isolates 2–3 and 2–8 due to large variations in results. Susceptibility to peptidomimetic 1 varies widely within the
populations. Solid line: population MIC; punctuated line: wt MIC (8 mg/mL).
doi:10.1371/journal.pone.0073620.g003
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(p.0.05 for all). However, one isolate from lineage no. 7 (i.e. 7-3)
showed a significant decrease (p,0.05) in growth rate as
compared to E. coli ATCC 25922 and five other isolates from
lineage no. 7 (i.e. 7-2, 7-4, 7-5, 7-6 and 7-8) showed a highly
significant decrease (p,0.01) in growth rate relative to the wild-
type strain. The growth rates of the remaining isolates from
lineage no. 7 (i.e. 7-1, 7-7, 7-9 and 7-10) were not significantly
different from E. coli ATCC 25922 (p.0.05). Next, we determined
the growth rate of one representative isolate from each lineage (i.e.
2-7, 4-4, 5-6 and 7-3) in the presence of sub-inhibitory
concentrations of peptidomimetic 1. As expected from their
MIC values, isolates 4-4 and 5-6 were not able to grow at low
inoculums at concentrations around the MIC, and hence their
growth rates in supplemented media could not be calculated.
Despite the high MIC values found for 2-7 and 7-3 (128 mg/mL,
Figure 3) a pronounced effect on growth was seen even at very low
concentrations of peptidomimetic 1. The growth rates of both
isolates were significantly reduced at a peptidomimetic concen-
tration of 8 mg/mL corresponding to wt MIC or 1/166isolate
MIC (2–7: p,0.01; 7-3: p,0.05). Remarkably, a significantly
reduced growth rate was also seen for isolate 2–7 (p,0.01) at a
concentration of 4 mg/mL i.e. 1/326MIC. In comparison, a
reduced growth rate was not seen for E. coli ATCC 25922 when it
was exposed to 1/16 or 1/326wt MIC (p.0.05).
Whole-genome Sequencing
Twenty isolates (five from each of the four selected lineages)
exposed to peptidomimetic 1 and three isolates cultured with
MilliQ water as well as the ancestral wild type were whole-genome
sequenced. The wild type (E. coli ATCC 25922) was de novo
assembled creating 135 contigs of 5.12 MB. The 135 contigs of the
ancestral strain then served as a reference for identifying SNPs and
DIPs in the evolved isolates. The sequenced isolates were divided
into three groups based on their susceptibility towards peptidomi-
metic 1: (i) isolates with wt MIC (8 mg/mL), (ii) isolates with low
levels of resistance (4–8 6wt MIC), and (iii) isolates that were
highly resistant (8–166wt MIC) (Table 4). The pattern of SNPs/
DIPs varied between the lineages, but all isolates from lineages
no. 4 and 5 had acquired the same mutations (Table 5) indicating
clonality. Typically four to six mutations (resulting in amino acid
changes) were detected in each isolate. Four of five isolates from
lineage no. 2 and three of five isolates from lineage no. 7 displayed
identical mutation patterns, albeit with difference between the two
lineages. Although there were clear differences in the exact
mutations between isolates from separate lineages, most (9 of 16)
were present in genes/proteins related to surface structures of the
bacterial cell. Only one mutation in the gadB gene encoding
glutamate decarboxylase was found in all 20 isolates, however, this
mutation was also detected in the control isolates. All three
controls contained ,100 amino acid-changing mutations indicat-
ing that without selection pressure the population will evolve
rapidly. We identified three SNPs and one DIP, which only were
present in six (of a total of eight) highly resistant isolates from
lineages no. 2 and 7. Five of these six isolates belonged to lineage
no. 2, and hence these are likely clonal. Using BLAST it was
determined that the four mutations were located in genes encoding
a hypothetical protein, a putative outer membrane transporter, a
macrolide transporter, and the membrane-bound lytic murein
transglycosylase D (mltD), respectively. No change was seen in the
susceptibility of the five isolates to the macrolide erythromycin as
compared to the wild type (not shown). The SNP in the mltD gene
caused a change of amino acid 55 from proline (nonpolar) to
glutamine (polar), but the effect of this on the secondary structure
of the protein is unknown [38]. However, these four mutations
were not found in two other isolates, 7-3 and 7-4 that also
displayed high levels of resistance towards peptidomimetic 1 (i.e.
MIC of 128 mg/mL). These two isolates only contained mutations
that were also present in two isolates with wt MIC, 7-9 and 7–10,
originating from the same lineage (Table 5). There was no pattern
in the mutations in the five isolates displaying low levels of
resistance to peptidomimetic 1 (4-1, 4-3, 5-6, 5-8, 5-9, Figure 3
and Table 5) that differentiated them from isolates with wt MIC.
Discussion
In this study it was demonstrated that Escherichia coli may
develop resistance to a synthetic antimicrobial peptide analogue
during prolonged continuous exposure to increasing concentra-
tions (Table 1), and this was consistently observed in all lineages.
To our knowledge this is the first demonstration of development of
heritable resistance to a peptidomimetic possessing an altered
Figure 4. Cross-resistance between peptidomimetic 1 and 2.
Association between Minimum Inhibitory Concentration (MIC) for
peptidomimetic 1 and peptidomimetic 2 against lineage no. 2 (black
circles) and lineage no. 5 (white circles). E. coli ATCC 25922 MIC is
highlighted with an asterisk (i.e. MIC values of 8 mg/mL and 64 mg/mL
for peptidomimetic 1 and 2, respectively). This data point is shared with
six of the ten isolates from lineage no. 5. Also, for lineage 2 three
isolates (2–7, 2–9 and 2–10) shared the same MIC values (peptidomi-
metic 1:256 mg/mL, peptidomimetic 2:512 mg/mL) as did the two
isolates 2–4 and 2–6 (peptidomimetic 1:96 mg/mL, peptidomimetic
2:512 mg/mL). All values are based on two biological replicates; the
mean value is displayed when results varied.
doi:10.1371/journal.pone.0073620.g004
Table 3. MIC (mg/mL) for wild-type E. coli and four
peptidomimetic-adapted isolates against peptidomimetic 1 in
standard MHB media and in MHB media supplemented with
25% human blood plasma.
MIC (8 mg/mL) in
Isolate MHB MHB +25% plasma Potentiationa
E. coli ATCC 25922 8 2 Weak
2–7 64–128 0.25–2 Strong
4–4 8 1–4 Weak
5–6 32–64 4–8 Weak
7–3 128 1–2 Strong
aAbility of plasma to interact synergistically with peptidomimetic 1.
doi:10.1371/journal.pone.0073620.t003
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backbone structure. We have previously shown that these a-
peptide/b-peptoid hybrids are membrane-active [35]. For long, it
was believed that development of resistance to AMPs was unlikely
since these compounds target the bacterial Achilles’ heel i.e. the
plasma membrane structure [12]. Although these peptidomimetics
indeed target the structural features of the bacterial membrane,
the investigated wild-type strain of E. coli were found capable of
developing a mechanism of resistance that circumvents the
membrane activity of the peptidomimetics. A few studies have
shown that resistance may develop towards other AMPs. The most
comprehensive of these studies was performed with pexiganan, an
analogue of the natural AMP magainin 2, against Pseudomonas
fluorescens and E.coli [29]. The authors demonstrated high levels of
heritable resistance in both bacteria showing that resistance
mechanisms may evolve as a result of a continuous selection
pressure exerted by a single compound. Other studies have not
found AMP resistance as a result of continuous selection with
natural or synthetic AMPs [30,31,39], however, these studies were
performed with sub-inhibitory concentrations of the AMP without
any attempts to increase the concentration. We speculate that the
development of resistance shown by Perron et.al. [29] and
demonstrated in the present study may be due to the gradual
two-fold increments in the concentration starting from a very low
level (1/166wt MIC) of the AMP used for selection and, hence
allowing sufficient time for mutation and selection.
E. coli bacteria possess a large mutational reservoir for increased
resistance to antibiotics [40]. The differences observed in the level
of resistance and stability (Table 1) indicate that distinct
mutational events may have taken place between and within the
lineages. We have shown that the MIC values for the
peptidomimetic varied between individual isolates from all four
lineages that were selected for further investigation (Figure 3).
Interestingly, we did not identify any isolates displaying the
population MIC in either lineage no. 2, 4 or 5; we hypothesize
that this could be due to: (i) lack of stability of the population, or (ii)
presence of only small fractions of highly resistant mutants. In the
development of resistance to antibiotics, bacterial charity (i.e.
production of indole) has been proposed to confer protection to
less resistant clones in a heterogeneous population [41]. Also, it is
possible that epigenetic events such as changes in gene expression
may provide temporary protection of the entire population [42].
Since previous studies had indicated moderate mutation rates
for polymyxins [43,44], we selected for polymyxin B resistance in
parallel experiments. Thus, we found indications of a higher
mutation rate for polymyxin B than that of peptidomimetic 1 as
spontaneous growth of one of the controls at 46wt MIC was only
seen for the former (not shown). No cross-resistance was detected
between peptidomimetic 1 and polymyxin B, independently of
which compound had been used as the selection agent,
demonstrating that different mechanisms must confer resistance
against these compounds. Resistance to polymyxins has been
demonstrated several times to be related to modification of the
bacterial outer membrane, in particular of the lipopolysaccharide
(LPS) layer [43,45,46]. Such modifications are most often
mediated by two-component systems, which have been widely
studied for their role in resistance to AMPs [23–25]. Two-
component systems are often associated with adaptive (inducible)
resistance, whereas resistance to polymyxin B in this case proved
heritable in unsupplemented media., However, two-component
systems e.g. PhoPQ, PmrAB and ParRS have also been shown to
be sites for mutations leading to constitutive modifications of the
cell surface [47–49]. A pmrA constitutive polymyxin B resistant E.
coli mutant has previously been reported [47], and hence it is
possible that two-component systems may have a role in the
development of resistance in the present study, even though
resistance was found to be stable.
Likewise, resistance to peptidomimetic 1 was also heritable in
the examined peptidomimetic-resistant isolates. To investigate the
resistance mechanism, we tested for cross-resistance to conven-
tional antibiotics and natural AMPs. Resistance to aminoglyco-
sides may be mediated by LPS modifications [43], but we could
not demonstrate any cross-resistance to gentamicin representing
this type of antibiotics. Similarly, no change was seen in the
susceptibility of the isolates to a b-lactam drug (ampicillin).
Importantly, we found no evidence of cross-resistance to a range of
natural and semi-synthetic AMPs indicating that the resistance
mechanism for membrane-active AMPs is not universal. However,
pronounced cross-resistance was found to other peptidomimetics
with the same scaffold (i.e. 2 and 3, Figure 1), demonstrating that:
(i) replacement of homoarginine by lysine and extending the length
(i.e. 12-meric 1 vs. 16-meric 2), or (ii) decreasing the degree of
chirality by incorporation of achiral b-peptoid residues (i.e.
peptidomimetic 3) does not preclude cross-resistance. Especially,
cross-resistance to the latter peptidomimetic is interesting since the
extent of chirality influences the secondary structure, which
generally is believed to have a marked impact on the mechanism
of action of membrane-active AMPs and peptidomimetics [50],
and also have been shown to have a significant effect on the ability
of these peptidomimetics to interact with human cells [51,52].
A significant dilemma in the development and use of AMP/
peptidomimetics against systemic infections is that since these
compounds mimic the structure of endogenous human defence
Table 4. Grouping of genome-sequenced peptidomimetic-adapted isolates based on comparison to wild type (wt) MIC value
(8 mg/mL).
Isolates with wt MIC Low resistance isolates: 4–86wt MIC High resistance isolates: 8–166wt MIC
4–4 4-1 2–4
4–6 4-3 2–6
4–10 5-6 2–7
5–2 5-8 2–9
5–4 5-9 2–10
7–9 7–3
7–10 7–4
7–7
doi:10.1371/journal.pone.0073620.t004
Peptidomimetic Resistance by Adaptive Evolution
PLOS ONE | www.plosone.org 7 September 2013 | Volume 8 | Issue 9 | e73620
T
a
b
le
5
.
D
is
tr
ib
u
ti
o
n
o
f
si
n
g
le
-n
u
cl
e
o
ti
d
e
p
o
ly
m
o
rp
h
is
m
s
(S
N
P
s)
an
d
d
e
le
ti
o
n
-i
n
se
rt
io
n
p
o
ly
m
o
rp
h
is
m
(D
IP
s)
th
at
ca
u
se
d
an
am
in
o
ac
id
ch
an
g
e
an
d
h
ad
a
fr
e
q
u
e
n
cy
ab
o
ve
8
0
%
in
th
e
p
e
p
ti
d
o
m
im
e
ti
c-
ad
ap
te
d
g
e
n
o
m
e
-s
e
q
u
e
n
ce
d
is
o
la
te
s.
L
in
e
a
g
e
2
a
L
in
e
a
g
e
4
L
in
e
a
g
e
5
L
in
e
a
g
e
7
G
e
n
e
n
a
m
e
G
e
n
e
p
ro
d
u
ct
2
-
4
1
2
-6
1
2
-7
1
2
-9
1
2
-1
0
1
4
-1
2
4
-3
2
4
-4
3
4
-6
3
4
-1
0
3
5
-2
3
5
-4
3
5
-6
2
5
-8
2
5
-9
2
7
-3
1
7
-4
1
7
-7
1
7
-9
3
7
-1
0
3
C
o
n
tr
o
l
fh
u
F
Fe
rr
ic
io
n
re
d
u
ct
as
e
X
–
P
u
ta
ti
ve
au
to
tr
an
sp
o
rt
e
r
X
X
X
X
X
X
m
lt
D
M
u
re
in
tr
an
sg
ly
co
sy
la
se
D
X
X
X
X
X
X
m
a
cB
b
M
ac
ro
lid
e
tr
an
sp
o
rt
e
r
X
X
X
X
X
x
X
x
x
x
x
x
x
x
x
X
eu
tE
G
J
Et
h
an
o
la
m
in
e
u
ti
liz
at
io
n
X
–
H
yp
o
th
e
ti
ca
l
p
ro
te
in
d
X
X
X
X
X
X
g
a
d
B
G
lu
ta
m
at
e
d
e
ca
rb
o
xy
la
se
d
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
iu
cC
Si
d
e
ro
p
h
o
re
b
io
sy
n
th
e
si
s
X
X
X
X
X
X
X
X
X
X
X
X
X
X
m
a
cA
c
M
ac
ro
lid
e
tr
an
sp
o
rt
e
r
X
X
X
X
X
X
X
X
X
X
x
x
X
x
b
a
m
A
O
u
te
r
m
e
m
b
ra
n
e
p
ro
te
in
as
se
m
b
ly
X
X
X
X
b
lc
O
u
te
r
m
e
m
b
ra
n
e
lip
o
ca
lin
X
X
X
X
q
u
u
Q
Q
in
p
ro
p
h
ag
e
an
ti
te
rm
in
at
io
n
X
X
X
X
–
H
yp
o
th
e
ti
ca
l
p
ro
te
in
X
X
X
X
yh
jL
C
e
llu
lo
se
sy
n
th
as
e
su
b
u
n
it
B
cs
C
d
X
a
1
is
o
la
te
s
w
it
h
h
ig
h
le
ve
ls
o
f
re
si
st
an
ce
i.e
.
8
–
1
66
w
ild
ty
p
e
M
IC
,
2
is
o
la
te
s
w
it
h
in
te
rm
e
d
ia
te
le
ve
ls
o
f
re
si
st
an
ce
i.e
.
4
–
86
w
t
M
IC
;
3
Is
o
la
te
s
w
it
h
w
ild
ty
p
e
M
IC
.
b
T
w
o
SN
P
s
w
e
re
p
re
se
n
t
in
th
e
m
a
cB
g
e
n
e
:
o
n
e
SN
P
ca
u
si
n
g
am
in
o
ac
id
3
1
9
in
th
e
p
ro
te
in
to
ch
an
g
e
fr
o
m
A
sp
to
T
yr
(X
)
an
d
o
n
e
ca
u
si
n
g
am
in
o
ac
id
5
0
5
to
ch
an
g
e
fr
o
m
T
rp
to
Le
u
(x
).
c
T
w
o
SN
P
s
w
e
re
p
re
se
n
t
in
th
e
m
a
cA
g
e
n
e
:
o
n
e
SN
P
s
ca
u
si
n
g
am
in
o
ac
id
9
1
in
th
e
p
ro
te
in
to
ch
an
g
e
fr
o
m
V
al
to
G
ly
(X
)
an
d
o
n
e
ca
u
si
n
g
am
in
o
ac
id
2
0
5
to
ch
an
g
e
fr
o
m
V
al
to
Le
u
(x
).
d
D
IP
m
u
ta
ti
o
n
s;
al
l
o
th
e
r
m
u
ta
ti
o
n
s
ar
e
SN
P
s.
d
o
i:1
0
.1
3
7
1
/j
o
u
rn
al
.p
o
n
e
.0
0
7
3
6
2
0
.t
0
0
5
Peptidomimetic Resistance by Adaptive Evolution
PLOS ONE | www.plosone.org 8 September 2013 | Volume 8 | Issue 9 | e73620
peptides, resistance to these compounds might compromise our
innate immune defence [28]. We investigated this by determining
whether acquisition of resistance influences the activity of other
innate immune factors present in the blood. Surprisingly, the
growth of the two peptidomimetic-resistant isolates 2-7 and 7-3
was hampered significantly in the presence of blood plasma.
Hence, acquisition of resistance to a peptidomimetic in fact
renders the bacteria more susceptible to at least the soluble
components of the innate immune system present in blood plasma.
We hypothesize that changes in the structure of the outer
membrane confer an increased susceptibility to yet unknown
plasma components that presumably interact with the bacterial
membrane. Notably, inactivation of complement by heat-treat-
ment eliminated the bactericidal activity of plasma against the
peptidomimetic-resistant isolates. We were also interested in
investigating the activity of peptidomimetic 1 towards the resistant
isolates in the presence of plasma. Interestingly, peptidomimetic
resistance of the two isolates 2-7 and 7-3 was abolished in the
presence of 25% plasma (Table 3), suggesting that the activity of
plasma components renders the resistance mechanism against
peptidomimetic activity ineffective or even abolishes it completely.
Plasma potentiation against resistant strains has been demonstrat-
ed for antibiotics [53]. An explanation might be that the resistance
mechanisms involve modifications in the outer cell layer, which
confers peptidomimetic resistance, but also enhances susceptibility
to plasma components. However, plasma potentiation of the
activity of peptidomimetics is most likely due to synergy as
previously reported [54] as the wild-type strain also exhibited a
diminished MIC value when tested in the presence of plasma.
Whole-genome sequencing of twenty selected isolates repre-
senting four resistant lineages revealed several mutations that were
conserved between lineages, but also mutations that were
conserved within lineages indicating that these isolates may be
clonal (Table 5). Most of these mutations were found to be related
to modification of the cell envelope, which apparently did not
seem to entail a fitness cost in resistant isolates since the growth
rates of the majority of isolates were comparable to that of the
ancestral wild-type strain. No mutations were found in genes
encoding known two-component systems. Surprisingly, four
mutations had occurred in all ten sequenced isolates originating
from lineages no. 4 and 5, which all displayed wild type MIC or
low levels of resistance towards peptidomimetic 1 even though the
two lineages had a very high population MIC. However, none of
these isolates had a MIC exceeding that of the wild-type strain,
which may possibly be due to a very low frequency of resistance-
conferring mutations in these two lineages. For isolates from
lineages no. 2 and 7 two patterns of mutations could be
distinguished (Table 5). Thus, the five isolates from lineage no. 2
that were all highly resistant, as well as a highly resistant isolate
from lineage no.7 (i.e. 7-7), all shared the same three SNPs and
one DIP. Though the presence of the same mutations in lineage
no. 2 indicate that these may be clonal, one of these isolates also
had two additional mutations, and in addition it is very interesting
that these four common mutations were also found in an isolate
(7–7) originating from another lineage. One of the four mutations
is a SNP in the gene encoding the MltD protein, a membrane-
bound lytic murein transglycosylase responsible for peptidoglycan
reorganization. This SNP causes a change in amino acid residue
55 of the protein from the nonpolar proline to the polar glutamine,
and it is conceivable that this may give rise to changes in the
secondary structure, and thereby in the activity of MltD. This is
corroborated by a study in Vibrio anguillarum where it was shown
that inactivation of the mltD gene results in resistance to
conventional antibiotics [55]. The remaining four isolates from
lineage no. 7, of which isolates 7-3 and 7-4 can be considered
highly resistant, all displayed the same alternative mutations
(Table 5). Hence, it is likely that resistance in these two isolates is
due to unidentified mutations in non-coding regions since these
isolates appear to be as stable as the population they originate from
and therefore their resistance is not likely to be due to population-
based resistance mechanisms e.g. epigenetic inheritance [42].
In conclusion, E. coli was found capable of developing heritable
resistance to an a-peptide/b-peptoid peptidomimetic, and this
constitutes the first example where this has been demonstrated for
a backbone-modified AMP analogue. Importantly, the acquisition
of bacterial resistance towards this type of peptidomimetic did not
give rise to cross-resistance to AMPs and did not impair the innate
immune system to eliminate the resistant isolates, regardless of
which mutations had been induced in the resistant isolates. Thus,
in the present study resistance appears to be directly linked to the
unnatural scaffold and sequence design displaying alternating
cationic and hydrophobic residues. The fact that the developed
resistance came with a concomitant increased susceptibility
towards soluble plasma constituents (most likely complement)
indicate that these peptidomimetics indeed may have a potential as
future therapeutics. In addition, this study confirm our previous
finding that the present peptidomimetics interact synergistically
with plasma [54] as killing of all resistant mutants under these
conditions were potentiated to such a degree that the MICs of
peptidomimetic 1 was similar to or lower than that of the
archetype wild-type ancestor.
However, the finding that resistance in fact may be developed
towards peptidomimetics in vitro unequivocally show that the
resistance issue should be investigated for all types of compounds
presently undergoing development similarly to how potential
immuno-modulatory properties are already taken into consider-
ation today.
Materials and Methods
Bacterial Strain and Culture Conditions
All experiments were performed with Escherichia coli ATCC
25922. Stock cultures of the wild-type strain and lineage isolates
were stored at –80uC in 4% (w/v) glycerol, 0.5% (w/v) glucose,
2% (w/v) skimmed milk powder and 3% (w/v) tryptone soy
powder. Lineage populations were frozen at –80uC in 50% (w/v)
glycerol. All experiments were performed at 37uC. Experiments
were carried out in cation-adjusted Mueller Hinton II broth
(MHB) (Becton Dickinson 212322) adjusted to pH 7.4 or in 1%
(w/v) peptone (Becton Dickinson 211677) for MIC determination
of natural AMPs. Brain Heart Infusion (BHI) (CM1135) with agar
(VWR 20768.292) 1.5% as gelling agent was used throughout for
colony plating.
Antibiotics and Synthesis of Peptidomimetics and
Natural AMPs
Polymyxin B (P4932), protamine (P4020), gentamicin (G3632),
ampicillin (A9518) and erythromycin (E6376) were purchased
from Sigma Aldrich. The a-peptide/b-peptoid peptidomimetics 1,
2 and 3 consisting of alternating repeats of cationic natural a-L-
amino acids and unnatural lipophilic b-peptoid residues (Figure 1)
were synthesized by solid-phase synthesis as previously described
[32,33]. KR-12 [56], IsCTp [16], PEP-1-K [15] and melittin were
prepared by automated microwave (MW)-assisted solid-phase
Fmoc-based synthesis on a CEM Liberty microwave peptide
synthesizer using a Rink amide resin (loading: 1.0 mmol/g). Fmoc
deprotection was performed with 20% piperidine-DMF at 75uC
(30 sec followed by 180 sec), while coupling was performed by
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using the appropriate Fmoc-protected building block (5.0 eq) with
DIC (5 eq.) and HOBt (5 eq.) in DMF at 75uC for 15 min.
Capping was applied after every fourth coupling with Ac2O-
DIPEA-NMP (1:2:3) at 65uC (30 sec, repeated once). Final
deprotection of the N-terminus was followed by cleavage and
simultaneously side chain deprotection with TFA-TIS-H2O
(95:2.5:2.5; 3 mL) for 60 min. The filtrate was collected and the
resin was eluted with DCM (2 mL) and TFA (26 2 mL). The
combined filtrates were conc. in vacuo, and then co-evaporated with
toluene (36). The crude product was triturated with Et2O,
dissolved in MeCN-H2O (50:50) containing 0.1% TFA, and then
purified by preparative HPLC. Finally the product was dissolved
in water (1 mL) and lyophilized. Analytical HPLC was carried out
on a Phenomenex Luna C18 (2) (3 mm) column (15064.60 mm)
using binary mixtures of eluent A (H2O-MeCN-TFA 95:5:0.1) and
eluent B (H2O- MeCN-TFA 5:95:0.1) for elution with a flow rate
of 0.8 mL/min by using a linear gradient of 10–60% B during
30 min. Peptides were detected with UV at l=220 nm.
Preparative HPLC was performed on a Luna C18 (2) (5 mm)
column (250621.20 mm) with an Agilent 1100 LC system with a
multiple-wavelength UV detector. Elution was performed with a
linear gradient of 10–40% during 20 min at a flow rate of 20 mL/
min. Peptides were detected with UV at l=220 nm. LC-HRMS
was performed with a Phenomenex Luna C18 (2) (3 mm) column
(15064.6 mm) using binary mixtures of eluent C (H2O-MeCN-
HCOOH 95:5:0.1) and D (H2O-MeCN-HCOOH 5:95:0.1).
Elution was performed with a linear gradient of 10–60% D
during 30 min at a flow rate of 0.5 mL/min. HRMS spectra (DM
,5 ppm) were obtained using a Bruker MicrOTOF-Q II
Quadropol MS detector. Analyt. HPLC (.97% purity at
220 nm) retention times (RT): RT=16.85 min for KR-12;
RT=28.75 min for mellitin; RT=17.74 min for IsCTp;
RT=17.79 min for Pep-1-K.
Peptidomimetics and AMPs were solubilised to a stock of
10 mg/mL in sterile MilliQ water and stored at 220uC.
Polymyxin B was solubilised to a stock of 10 mg/mL in sterile
MilliQ water, filter-sterilized and stored at 5uC. Protamine was
solubilised to a concentration of 1024 mg/mL in sterile MilliQ
water and used immediately. Gentamicin and ampicillin were
solubilised to a stock of 25 mg/mL in sterile MilliQ water, filter-
sterilized and stored at 5uC and 280uC, respectively. Erythromy-
cin was solubilised to a stock of 10 mg/mL in 96% ethanol and
prepared fresh for each experiment.
Continuous Selection Experiment
Continuous selection of resistance was performed for peptido-
mimetic 1 (Figure 1) and for the clinically relevant natural
antimicrobial peptide, polymyxin B. A bacterial suspension of a
single colony of E. coli ATCC 25922 was re-inoculated (10 ml) five
times in unsupplemented MHB (990 ml). It was then re-inoculated
in MHB supplemented with peptidomimetic 1 (ten lineages) or
polymyxin B (ten lineages), and after ten re-inoculations at
constant peptidomimetic or polymyxin B concentration, the
concentrations were doubled. The starting concentration was 1/
16 of the Minimum Inhibitory Concentration, MIC (i.e. 0.5 mg/
mL and 0.0625 mg/mL, respectively), and this was increased to
326MIC during the course of the experiment. Four lineages
grown in MHB with MilliQ water were included as control. Re-
inoculations were performed twice a day, but were reduced to
once a day when growth was slower as assessed by turbidity of the
cultures. The total number of passages (supplemented with
peptidomimetic/AMP) was 77 times equivalent to approx. 500
generations. For each increase in concentration the lineages were
preserved as freezing stocks. Ten colony isolates were randomly
selected from each lineage population at 326MIC and preserved
as freezing stocks.
Determination of MIC
MIC was determined by using the micro-dilution method
according to guidelines of the Clinical and Laboratory Standards
Institute [57]. Peptidomimetic 1 and erythromycin 1:2 serial
dilutions were prepared from 1024 mg/mL stock solutions to give
a final range of 512-0.5 mg/mL in the wells. Ampicillin 1:2 serial
dilutions were prepared from a 256 mg/mL stock solution to give a
final range of 128-0.13 mg/mL in the wells. Polymyxin B and
gentamicin 1:2 serial dilutions were prepared from a 64 mg/mL
stock solution to give a final range of 32-0.03 mg/mL in the wells.
Also, 1:2 serial dilutions of the AMPs KR-12, IsCTp, melittin and
PEP-1-K were prepared from 64 mg/mL stock solutions to give a
final range of 32-0.03 mg/mL in the wells; however this was
performed in 1% peptone instead of in MHB since activity was
drastically diminished in the latter (not shown).
The population lineages were tested for their susceptibility
towards peptidomimetic 1, polymyxin B, gentamicin and ampi-
cillin. Single-culture isolates selected from these populations were
additionally tested against peptidomimetic 1, polymyxin B,
erythromycin and the five reference AMPs. To estimate the level
of cross-resistance to closely related peptidomimetics, MIC
determinations were performed for peptidomimetics 2 and 3
(Figure 1) towards selected isolates. The bacterial suspensions were
grown overnight in MHB at 37uC for determination of the
population MIC, or individual isolates were grown overnight on
non-selective BHI agar at 37uC. MIC determination performed on
the wild-type strain using re-suspended colonies, as well as on a
culture grown overnight in broth, showed that pre-growth in broth
had minimal effect on the MIC results. In order to determine the
population MIC, the respective compound (peptidomimetic 1 or
polymyxin B) was added to give a concentration corresponding to
326MIC to maintain the selection pressure of the freezer-revived
lineages, and then MIC determination was performed on the
outgrown population (i.e. ,109 CFU/mL). In all experiments,
bacterial cells were suspended in 0.9% saline to give a turbidity of
0.13 at OD546 (approximately 1610
8 CFU/mL) and diluted in
MHB pH 7.4 to a final concentration of 56105 CFU/mL in each
well. Polypropylene plates (Nunc 442587) were used to minimize
peptide binding, and the incubation time was 18–20 hours at
37uC. Incubation time was additionally extended up to 44 hours
for the individual isolates due to a potential effect of growth rate on
the outcome, but no effect was seen of this (not shown). MIC was
found in a minimum of two technical (population MIC) or
biological (isolate MIC) replicates as the lowest concentration of
the AMP or antibiotic where no visible growth was observed.
Effect of Human Blood Plasma on Growth and
Susceptibility
Four isolates, i.e. 2-7, 4-4, 5-6 and 7-3, a representative isolate
from four different lineages, were revived from freeze storage. The
four isolates were grown in 25–50% blood plasma and in 25–50%
heat-inactivated plasma as previously described [54]. Blood
plasma was obtained from two different blood donors using
sodium citrate as anticoagulant and experiments were performed
on at least two independent days. Both donors were fully informed
about the study and purpose and a written consent has been
received. According to the Danish Science Ethics Committee, the
study did not need approval from the Committee (Protocol nr H-
2-2013-FSP45). MIC determinations for hydrogen peroxide and
lysozyme were performed in biological duplicates as described
above to see whether resistance in isolate 2-7 also conferred
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elevated MIC values towards innate immune factors. Lastly, MIC
against peptidomimetic 1 was determined as described above in
the presence of 25% plasma (chosen due to lack of growth of
several isolates in 50% plasma) to determine whether this would
decrease or abolish the elevated MICs of resistant isolates. For this
the 1:2 serial dilutions were made in MHB with 50% blood plasma
added to give a final concentration of 25% plasma in the wells.
Stability of Resistance
Frozen stocks were reconditioned in unsupplemented MHB
media for five transfers (,35 generations) at 37uC. The heritability
of resistance was established through MIC determination of
bacterial populations as described above.
Fitness Cost
To evaluate whether resistance altered the physiology of the
isolates, we determined the growth rate of all forty isolates from
lineage 2, 4, 5 and 7 as well as of E. coli ATCC 25922 in
unsupplemented MHB media. Additionally, we determined the
growth rate of the four isolates 2-7, 4-4, 5-6 and 7-3, in MHB
supplemented with peptidomimetic 1 at K6wild type MIC or
16wild type MIC (i.e. 4 and 8 mg/mL). To correct for the higher
MIC values of isolates 2-7 and 7-3 (which were 166above the wild
type MIC) we also determined the growth rate for E. coli ATCC
25922 in MHB supplemented with 1/32 and 1/166wild type
MIC. Optical density readings were obtained at 570 nm at 10–12
minute increments on cultures grown at 37uC over 24 hours
(unsupplemented MHB) or 72 hours (supplemented MHB) using
the automated Bioscreen C system (Labsystems, Helsinki, Fin-
land). Growth rates were found using linear regression on ln(initial
CFU/mL) vs. detection time (i.e. the time until a 0.5 unit increase
in absorbance was reached) for inoculum sizes ranging from 102–
107 CFU/mL [58]. Data were analysed in GraphPad Prism
version 4.03 using One-Way ANOVA followed by Dunnett’s Test
to correct for multiple testing. Control groups were E. coli ATCC
25922 (in the absence of peptidomimetic) or E. coli ATCC 25922/
isolates grown in unsupplemented media (in the presence of
peptidomimetic). Significance levels were in all tests set at p,0.05.
All experiments were performed in duplicate on at least two
independent days.
Whole-genome Sequencing
A total of twenty isolates from four peptidomimetic-exposed
lineages were chosen for whole-genome sequencing (Table 4). The
isolates were either high-level resistant or low-level resistant or
corresponded to wild type MIC. For comparison three isolates
from the controls were included. The genome sequence of the
ancestral wild type E. coli ATCC 25922 has not previously been
published and was therefore included as reference. This Whole
Genome Shotgun project has been deposited at DDBJ/EMBL/
GenBank under the accession number ASHD00000000. The
version described in this paper is version ASHD01000000.
Genomic DNA was extracted from each sample by using
phenol:chloroform:isoamyl alcohol and then precipitated with
isopropanol. Samples were treated with RNAse before quantifi-
cation and quality analysis using 1% agarose gel electrophoresis,
NanoDrop Spectrophotometer (Saveen Werner, Sweden) and
Qubit 2.0 Analyser (Invitrogen, United Kingdom). Libraries of
500 bp were used for 100 bp paired-end sequencing of genomes
using the Illumina sequencing technology on a HiSeq2000 with a
minimum coverage of 100 (Beijing Genomics Institute, Hong
Kong, China). E. coli ATCC 25922 was de novo assembled into
contigs using the CLCbio Genomics Workbench (Aarhus, Den-
mark) resulting in 135 contigs comprising 5,116,439 bp. Using this
procedure the 23 isolates were mapped with the 135 contigs as a
reference with a minimum coverage of 100, and then single-
nucleotide-polymorphism (SNPs) and deletion-insertion-polymor-
phism (DIPs) with a frequency above 80% were detected.
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